Recombinant Mouse P-Selectin/CD62P Protein
Beta LifeScience
SKU/CAT #: BLK-01418P-100UG

Mouse P-Selectin/CD62P on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Mouse P-Selectin/CD62P Protein
Beta LifeScience
SKU/CAT #: BLK-01418P-100UG
Collections: All products, High-quality recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Mouse P-Selectin/CD62P Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Trp42-Ala709. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | Q01102 |
Target Symbol | P-Selectin/CD62P |
Synonyms | FLJ45155; GMP140; GRMP; PADGEM; PSEL; P-Selectin; SELP; CD62P; CD62; LECAM3 |
Species | Mouse |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Trp42-Ala709 |
Mol. Weight | The protein has a predicted MW of 81.1 kDa. Due to glycosylation, the protein migrates to 110-130 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | P-selectin is critical in the progression of atherosclerosis as evidenced by knockout animal models where P-selectin knockout mice crossed with apoE deficient mice exhibit significantly reduced atherosclerosis and leukocyte recruitment in the plaque. A soluble form of P-selectin also exists, which may have pro-atherogenic and pro-thrombotic effects. Thus targeting of P-selectin remains a strong clinical candidate for developing novel therapeutic strategies in inflammatory diseases. |